News | Sutro Biopharma, Inc.

Sutro Biopharma Earns Milestone Payment from Cytokine Derivatives Collaboration with Merck

Apr 15, 2021

– Initiation of an IND enabling toxicology study for the first program under the 2018 collaboration oncytokine derivatives earns a $15 million milestone payment from Merck SOUTH SAN FRANCISCO, Calif., April 15, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a...

Sutro Biopharma to Present at Two Upcoming Investor Conferences

Apr 8, 2021

SOUTH SAN FRANCISCO, Calif., April 8, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...

Open Letter from CEO, Bill Newell

Mar 31, 2021

I Stand in Support of our AAPI Community I want to address the violence and discrimination towards our AAPI community; it has been there for hundreds of years. It is now apparent that it was, in some cases, under-reported or ignored. Most certainly it was greatly...

Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board

Mar 22, 2021

SOUTH SAN FRANCISCO, Calif., March. 22, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer...

Sutro Biopharma Reports Full Year 2020 Financial Results and Provides Business Highlights and 2021 Anticipated Milestones

Mar 18, 2021

- Year-end 2020 cash, cash equivalents and marketable securities of $326.5 million, with projected runway into the second half of 2023 - Four antibody-drug conjugate programs are now in the clinic that were discovered through Sutro’s proprietary and integrated...

Sutro Biopharma Presents at the 11th Annual World ADC Europe 2021 – PowerPoint Presentation

Mar 10, 2021

Download the presentation, CLICK HERE

Bill Newell, CEO Interviewed by Biotech 2050

Feb 24, 2021

Episode 47. Next Generation Cell Free Cancer and Autoimmune Therapeutics, Bill Newell, CEO, Sutro Biopharma

Sutro Biopharma to Participate in the Cowen 41st Annual Healthcare Conference

Feb 23, 2021

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...

Sutro Biopharma Announces First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian Cancer

Jan 21, 2021

SOUTH SAN FRANCISCO, Calif., Jan. 21, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...